By Sriparna Roy (Reuters) -Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory bowel disease (IBD) drugs and expanding its footprint in the multi-billion dollar market. Shares of Waltham, Massachusetts-based Morphic surged 76% to $56.15 in premarket trading on Lilly's offer of $57 per share, which represents a 79% premium to stock's last closing price. Through the deal, Lilly will procure an experimental oral IBD treatment that offers patients a more convenient dosing option compared to other injectable therapies, including its IBD drug Omvoh that was approved last year. ADVERTISEMENT Along with Lilly, other drugmakers such as Abbvie Inc, Pfizer and Johnson & Johnson are also jostling for a share of the bowel disease market. IBD collectively refers to two conditions - Crohn's disease and ulcerative colitis- that are characterized by chronic inflammation of the gastrointestinal tract and are caused by abnormal reactions of the immune system. Lilly counts its IBD drug, Omvoh, among its future growth drivers, besides its blockbuster weight loss treatment Zepbound and diabetes drug Mounjaro. Morphic's lead drug MORF-057 is being tested in three mid-stage studies to treat two bowel conditions called ulcerative colitis and Crohn's disease. Morphic is also developing other drugs, which are being tested in animals or test tube experiments, for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer. The companies expect the acquisition to close in the third quarter of 2024. The deal fits into Lilly's plans to diversify beyond obesity and adds to its string of recent "bolt-on" deals, said BMO analyst Evan Seigerman, referring to acquisitions below the $10 billion range. The Morphic deal comes after a spate of acquisitions by Lilly last year such as its $2.4 billion buyout of Dice Therapeutics and $1.4 billion agreement for Point Biopharma Global. (Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic deal
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...